share_log

424B3: Prospectus

424B3: Prospectus

424B3:募資說明書
美股sec公告 ·  05/17 17:10
Moomoo AI 已提取核心訊息
eFFECTOR Therapeutics, Inc., a biopharmaceutical company listed on the Nasdaq Capital Market under the symbols EFTR and EFTRW, filed a prospectus supplement on May 17, 2024. This filing updates and amends their previous prospectus dated April 2, 2024, and includes information from their Current Report on Form 8-K filed on the same day. The company's common stock and warrants closed at $1.98 and $0.02 respectively on May 16, 2024. eFFECTOR Therapeutics has been notified by Nasdaq that it has not met the Minimum Value of Listed Securities requirement of $35 million for the past thirty consecutive business days. The company has until November 12, 2024, to regain compliance with Nasdaq's continued listing requirements. Failure to do so may result in delisting. eFFECTOR Therapeutics is considering options to address the compliance issue but there is no guarantee of maintaining its listing.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company listed on the Nasdaq Capital Market under the symbols EFTR and EFTRW, filed a prospectus supplement on May 17, 2024. This filing updates and amends their previous prospectus dated April 2, 2024, and includes information from their Current Report on Form 8-K filed on the same day. The company's common stock and warrants closed at $1.98 and $0.02 respectively on May 16, 2024. eFFECTOR Therapeutics has been notified by Nasdaq that it has not met the Minimum Value of Listed Securities requirement of $35 million for the past thirty consecutive business days. The company has until November 12, 2024, to regain compliance with Nasdaq's continued listing requirements. Failure to do so may result in delisting. eFFECTOR Therapeutics is considering options to address the compliance issue but there is no guarantee of maintaining its listing.
Effector Therapeutics, Inc. 是一家在納斯達克資本市場上市的生物製藥公司,股票代碼爲EFTR和EFTRW,該公司於2024年5月17日提交了招股說明書補充文件。該文件更新並修訂了他們先前於2024年4月2日提交的招股說明書,幷包括他們當天提交的8-K表最新報告中的信息。該公司的普通股和認股權證於2024年5月16日分別收於1.98美元和0.02美元。納斯達克已通知Effector Therapeutics,該公司在過去連續三十個工作日中未達到3500萬美元的上市證券最低價值要求。該公司必須在2024年11月12日之前重新遵守納斯達克的持續上市要求。不這樣做可能會導致退市。Effector Therapeutics正在考慮解決合規問題的備選方案,但無法保證其繼續上市。
Effector Therapeutics, Inc. 是一家在納斯達克資本市場上市的生物製藥公司,股票代碼爲EFTR和EFTRW,該公司於2024年5月17日提交了招股說明書補充文件。該文件更新並修訂了他們先前於2024年4月2日提交的招股說明書,幷包括他們當天提交的8-K表最新報告中的信息。該公司的普通股和認股權證於2024年5月16日分別收於1.98美元和0.02美元。納斯達克已通知Effector Therapeutics,該公司在過去連續三十個工作日中未達到3500萬美元的上市證券最低價值要求。該公司必須在2024年11月12日之前重新遵守納斯達克的持續上市要求。不這樣做可能會導致退市。Effector Therapeutics正在考慮解決合規問題的備選方案,但無法保證其繼續上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息